Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts.
about
Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancerThymidine Phosphorylase in Cancer; Enemy or Friend?Systems pharmacology: network analysis to identify multiscale mechanisms of drug actionImpact of thymidine phosphorylase surexpression on fluoropyrimidine activity and on tumour angiogenesisOral fluoropyrimidines among the new drugs for patients with metastatic breast cancerPhase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapyThymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine.A multi-institutional phase II study of combination chemotherapy with S-1 plus cisplatin in patients with advanced non-small cell lung cancerPaclitaxel combined with capecitabine as first-line chemotherapy for advanced or recurrent gastric cancer.Rationally designed pharmacogenomic treatment using concurrent capecitabine and radiotherapy for glioblastoma; gene expression profiles associated with outcome.A phase I dose escalation study of a pharmacobiologically based scheduling of capecitabine and mitomycin C in patients with gastrointestinal malignanciesRadiosensitizers in cervical cancer. Cisplatin and beyond.Which endpoints should we use in evaluating the use of novel fluoropyrimidine regimens in colorectal cancer?Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer.Pilot study investigating the prognostic significance of thymidine phosphorylase expression in patients with metastatic breast cancer: a single institution retrospective analysisComparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation.Superior antitumor activity of trastuzumab combined with capecitabine plus oxaliplatin in a human epidermal growth factor receptor 2-positive human gastric cancer xenograft model.A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103).Effect of leucovorin on the antitumor efficacy of the 5-FU prodrug, tegafur-uracil, in human colorectal cancer xenografts with various expression levels of thymidylate synthaseEstablishment of a triple-negative type human breast cancer cell line that selectively metastasizes to the lung after orthotropic implantationUracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II studyCombination chemotherapy with carboplatin, capecitabine and epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer: a phase I/II trial.A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer.The expression of thymidine phosphorylase correlates with angiogenesis and the efficacy of chemotherapy using fluorouracil derivatives in advanced gastric carcinomaCapecitabine in the treatment of metastatic renal cell carcinomaExpression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinomaModulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancerCapecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trialPhase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors.Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer.Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate cancer.A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer.High expression of thymidine phosphorylase in basal-like breast cancers: Stromal expression in EGFR- and/or CK5/6-positive breast cancers.Different responses to two types of 5-fluorouracil prodrugs in combination with interferon-alpha in pulmonary metastases of renal cell carcinoma: a case report.
P2860
Q24651163-CD01A1FB-100D-4127-AF32-287CB1D8FC68Q26795650-7D58D5B3-DFE2-42BB-B680-5E9D7F807415Q26824166-08005C45-38A3-4618-A82A-90897DFAF514Q28345390-413AB0E3-2393-4AE9-A632-27F18153F80FQ28366029-94A5D7DA-64BB-41D0-8E73-8056E25BAF00Q33364558-2BE67EBB-4303-4F7F-AB6C-AB3F74474604Q33395508-F669C6EB-7816-4DE3-BBB5-04F4CFF44032Q33402690-3B85C033-908D-4E56-A571-66DC7F73505CQ33778285-E7571401-0EB1-4D25-9560-51A6012DDCC1Q33853588-6D0E4764-5009-4487-9BCF-DA20E1AEFEECQ34665196-1F27186E-756D-4A06-875A-2CCA11DE5126Q34684307-86CAEB1A-7C10-4A7F-9124-F5F9A0118358Q34711507-B1FBD138-88FA-4B25-A5AD-DE5BEB722745Q35032865-54F345C4-530E-4724-8BF3-36799A06DDCDQ35541901-39C25021-E9F5-4C94-873B-EABE0DD419ABQ35849214-5619C445-50D7-49F8-96C3-408F913DE3C5Q35948050-D4BBDDB2-9E34-47BB-897E-9F628F84268BQ36132957-21145018-C15C-4ABF-99FA-0F227AF29A6BQ36142392-D2D5A92C-B609-4225-8DB0-7A727C758DDBQ36230473-1AE36F2F-9DC0-4C7D-93AE-7F8ACF335F9CQ36609827-CB14C3BB-36A5-43F6-8B59-7835C1F24ADEQ36613503-AF64ADEF-A5F0-4F86-B4B0-966748395357Q36614734-2D836EC1-CCAF-450A-B4DB-43631E180EE1Q36619868-3BA2D503-6476-4163-9F09-851C0FA952ADQ36621825-91CB54C8-A424-48CB-BBC3-E9D235C87708Q36644051-E19B380F-BEDD-42E1-A7DE-5BFDC9BCE3B2Q36694314-453A5252-B5DC-43F7-864E-614222B20534Q36694859-D688B54C-3540-44FA-9263-F69822C919BEQ36695264-9E8010F1-BC2F-47D5-B814-1BF8ABE0F112Q37309238-02959016-F183-4A1A-86E3-B2930F79EF12Q37406114-61C365A1-BE96-45BB-A8EE-972D0530AAECQ37703380-0217C76F-1400-4BB9-B7BA-218038447DD2Q42242337-C49D61C3-4245-4E35-9C86-8BB43FB0AD8DQ42549684-A9460C6D-6FFC-4A1D-BDCD-C8AF4631AF2C
P2860
Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts.
description
1998 nî lūn-bûn
@nan
1998 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Positive correlation between t ...... rs in human cancer xenografts.
@ast
Positive correlation between t ...... rs in human cancer xenografts.
@en
Positive correlation between t ...... rs in human cancer xenografts.
@nl
type
label
Positive correlation between t ...... rs in human cancer xenografts.
@ast
Positive correlation between t ...... rs in human cancer xenografts.
@en
Positive correlation between t ...... rs in human cancer xenografts.
@nl
prefLabel
Positive correlation between t ...... rs in human cancer xenografts.
@ast
Positive correlation between t ...... rs in human cancer xenografts.
@en
Positive correlation between t ...... rs in human cancer xenografts.
@nl
P2093
P1433
P1476
Positive correlation between t ...... rs in human cancer xenografts.
@en
P2093
P304
P407
P577
1998-02-01T00:00:00Z